Skip to main content
NewslettersWatchlist

Theratechnologies Inc(THTX-Q)
NASDAQ

Today's Change
Delayed Last Update
Day Low3.34
Day High3.40
Open:3.36
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Theratechnologies Inc

Select a category then submit the form to load news
Tipranks
Theratechnologies Completes Acquisition by Future Pak
GlobeNewswire
Theratechnologies Announces Completion of Acquisition by Future Pak
Tipranks
Theratechnologies Receives Court Approval for Acquisition by Future Pak
GlobeNewswire
Theratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak
Tipranks
Theratechnologies Shareholders Approve Acquisition by Future Pak Affiliate
GlobeNewswire
Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak
Tipranks
Theratechnologies Launches EGRIFTA WR™ for HIV-Related Lipodystrophy
GlobeNewswire
Theratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy
Tipranks
Theratechnologies Gains Support for Future Pak Acquisition
GlobeNewswire
Theratechnologies Announces Independent Proxy Advisor Firms ISS and Glass Lewis Recommend Shareholders Vote “FOR” the Proposed Plan of Arrangement with Future Pak
Tipranks
Theratechnologies Announces Acquisition by CB Biotechnology with Significant Shareholder Premium
GlobeNewswire
Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak
Tipranks
Theratechnologies’ Ibalizumab Study: A Potential Game-Changer for Multidrug-Resistant HIV
Tipranks
Theratechnologies Announces Special Shareholder Meeting for September 2025
Tipranks
Theratechnologies Announces Acquisition Agreement with CB Biotechnology
Tipranks
Theratechnologies (THTX) Gets a Hold from JonesTrading
Tipranks
Theratechnologies Reports Q2 2025 Earnings and Acquisition
Tipranks
Theratechnologies Reports Q2 2025 Financial Results and Acquisition Agreement
GlobeNewswire
Theratechnologies Reports Financial Results for the Second Quarter 2025
The Globe and Mail
Small caps to watch: Biopharm stock surges on takeover deal, Cargojet wins contract extension, and more
Claude Vaillancourt, Research Associate, doing peptide synthesis in one of Theratechnologies' labs. Credit to Theratechnologies
Tipranks
JonesTrading downgrades Theratechnologies (THTX) to a Hold
Tipranks
Theratechnologies to be Acquired by Future Pak Affiliate
GlobeNewswire
Theratechnologies to Announce Second Quarter 2025 Financial Results
GlobeNewswire
Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak
GlobeNewswire
Theratechnologies Reports on its Annual Meeting of Shareholders
GlobeNewswire
Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV
GlobeNewswire
Theratechnologies Provides Update on Sale Process
GlobeNewswire
Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company
GlobeNewswire
Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements
GlobeNewswire
Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA
GlobeNewswire
Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Theratechnologies (THTX), KalVista Pharmaceuticals (KALV) and Mereo Biopharma Group Plc (MREO)

Profile

Theratechnologies, Inc. is a pharmaceutical company focusing on the development of therapeutic peptide products with an emphasis on growth-hormone releasing factor peptides. It's main product EGRIFTA is used for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy which is marketed primarily in the United States, Latin America, Africa, the Middle East, Europe, Russia, South Korea, Taiwan, and Thailand. Theratechnologies, Inc. is headquartered in Montreal, Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2025.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2025 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.